Omidenepag异丙酯与拉坦前列素治疗原发性开角型青光眼和高眼压的3期AYAME研究
这项3期随机、研究者设盲、阳性对照、平行组非劣效研究纳入190例日本原发性开角型青光眼或高眼压患者,比较Omidenepag异丙酯(OMDI)0.002%与拉坦前列素0.005%每日一次治疗4周的疗效和安全性。主要终点为第4周平均日间眼压较基线变化,OMDI非劣效于拉坦前列素,两组均未观察到严重不良事件。
要点
- OMDI 0.002%降眼压效果非劣效于拉坦前列素0.005%。
- OMDI组结膜充血和角膜增厚发生率高于拉坦前列素组。
- 两组均无严重不良事件及因研究药物停药。
核心结论
- OMDI 0.002%在降低高眼压或原发性开角型青光眼患者眼压方面非劣效于拉坦前列素0.005%,且耐受性良好。
研究设计与样本
- 3期、随机、研究者设盲、阳性对照、平行组、非劣效研究(NCT02623738)。
- 纳入190例日本原发性开角型青光眼或高眼压患者,经1-4周洗脱后按1:1随机分配至OMDI 0.002%或拉坦前列素0.005%每日一次治疗4周。
- 189例患者至少有1次基线后眼压测量。
- 于第1、2、4周在上午9:00、下午1:00和5:00测量眼压。
- 主要终点为第4周平均日间眼压较基线的变化,非劣效界值为1.5 mm Hg。
主要发现
- 基线时OMDI组和拉坦前列素组的平均日间眼压分别为23.78±1.73 mm Hg和23.40±1.51 mm Hg。
- 第4周时OMDI组眼压最小二乘均值±标准误降幅为-5.93±0.23 mm Hg,拉坦前列素组为-6.56±0.22 mm Hg,组间95%CI为0.01-1.26。
- 最常见的治疗相关眼部不良事件(OMDI vs 拉坦前列素)为结膜充血(23/94例[24.5%] vs 10/96例[10.4%])、角膜增厚(11/94例[11.7%] vs 1/96例[1.0%])和点状角膜炎(0/94例 vs 5/96例[5.2%])。
- 两组均未观察到严重不良事件,且无因研究药物停药者。
关键数值与推荐
- 非劣效界值为1.5 mm Hg。
- OMDI 0.002%与拉坦前列素0.005%每日一次,治疗4周。
- 主要终点为第4周平均日间眼压较基线变化。
临床怎么用
- 对于原发性开角型青光眼或高眼压患者,OMDI 0.002%可作为拉坦前列素的非劣效降眼压选择。
- 使用OMDI时需关注结膜充血和角膜增厚等眼部不良事件。
局限性
- 研究仅纳入日本患者,治疗和随访时间为4周。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the efficacy and safety of omidenepag isopropyl (OMDI), a selective, non-prostaglandin, prostanoid EP2 receptor agonist, in Japanese patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT). DESIGN: Phase III, randomized, investigator-masked, active-controlled, parallel-group, noninferiority study (ClinicalTrials.govNCT02623738). METHODS: After a washout period of 1-4 weeks, eligible patients were randomized (1:1) to OMDI 0.002% or latanoprost 0.005% once daily for 4 weeks. Intraocular pressure (IOP) was measured at 9:00 AM, 1:00 PM, and 5:00 PM at weeks 1, 2, and 4. The primary endpoint was the change from baseline in mean diurnal IOP at week 4. The noninferiority margin for OMDI versus latanoprost was 1.5 mm Hg. Adverse events (AEs) were recorded. RESULTS: Of the 190 patients randomized, 189 had at least 1 post-baseline IOP measurement. At baseline, patients who received OMDI or latanoprost had a mean ± SD diurnal IOP of 23.78 ± 1.73 mm Hg and 23.40 ± 1.51 mm Hg, respectively. At week 4, least-squares mean ± SE reduction in IOP from baseline with OMDI (-5.93 ± 0.23 mm Hg) was noninferior to that of latanoprost (-6.56 ± 0.22 mm Hg; 95% confidence interval between groups: 0.01-1.26). The most frequently reported treatment-related ocular AEs (OMDI vs latanoprost) were conjunctival hyperemia (23/94 patients [24.5%] vs 10/96 patients [10.4%]), corneal thickening (11/94 patients [11.7%] vs 1/96 patients [1.0%]), and punctate keratitis (0/94 patients vs 5/96 patients [5.2%]). No serious AEs were observed in either group, and there were no discontinuations related to the study drug. CONCLUSIONS: OMDI 0.002% was noninferior to latanoprost 0.005% in reducing IOP in patients with OHT or POAG and was well tolerated.
引用
- Aihara M, Lu F, Kawata H, et al. Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study. Am J Ophthalmol. 2020. PMID: 32533949. doi:10.1016/j.ajo.2020.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。